DK1432417T3 - Substituerede imidazolforbindelser og deres anvendelse til behandling af cancer - Google Patents

Substituerede imidazolforbindelser og deres anvendelse til behandling af cancer

Info

Publication number
DK1432417T3
DK1432417T3 DK02772370T DK02772370T DK1432417T3 DK 1432417 T3 DK1432417 T3 DK 1432417T3 DK 02772370 T DK02772370 T DK 02772370T DK 02772370 T DK02772370 T DK 02772370T DK 1432417 T3 DK1432417 T3 DK 1432417T3
Authority
DK
Denmark
Prior art keywords
cancer
treatment
imidazole compounds
substituted imidazole
substituted
Prior art date
Application number
DK02772370T
Other languages
Danish (da)
English (en)
Inventor
Francois Clerc
Isabelle Depaty
Odile Angouillant-Boniface
Stephanie Deprets
Chantal Carrez
Manfred Roesner
Francois Hamy
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK1432417T3 publication Critical patent/DK1432417T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
DK02772370T 2001-09-26 2002-09-26 Substituerede imidazolforbindelser og deres anvendelse til behandling af cancer DK1432417T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01402460A EP1298125A1 (en) 2001-09-26 2001-09-26 Substituted benzimidazole compounds and their use for the treatment of cancer
PCT/EP2002/011353 WO2003028721A2 (en) 2001-09-26 2002-09-26 Substituted benzimidazole compounds and their use for the treatment of cancer

Publications (1)

Publication Number Publication Date
DK1432417T3 true DK1432417T3 (da) 2008-06-16

Family

ID=8182891

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02772370T DK1432417T3 (da) 2001-09-26 2002-09-26 Substituerede imidazolforbindelser og deres anvendelse til behandling af cancer

Country Status (35)

Country Link
US (1) US7041668B2 (el)
EP (2) EP1298125A1 (el)
JP (1) JP4510450B2 (el)
KR (1) KR100891439B1 (el)
CN (1) CN100346786C (el)
AR (1) AR037096A1 (el)
AT (1) ATE386517T1 (el)
AU (1) AU2002337151B2 (el)
BR (1) BR0212856A (el)
CA (1) CA2461622C (el)
CO (1) CO5570675A2 (el)
CY (1) CY1107953T1 (el)
DE (1) DE60225159T2 (el)
DK (1) DK1432417T3 (el)
EA (1) EA006802B1 (el)
ES (1) ES2301682T3 (el)
GT (1) GT200200190A (el)
HK (1) HK1068551A1 (el)
HR (1) HRPK20040293B3 (el)
HU (1) HUP0401756A3 (el)
IL (1) IL161059A0 (el)
ME (1) MEP16808A (el)
MX (1) MXPA04002042A (el)
MY (1) MY135339A (el)
NO (1) NO327008B1 (el)
NZ (1) NZ531246A (el)
PA (1) PA8555501A1 (el)
PE (1) PE20030427A1 (el)
PL (1) PL369527A1 (el)
PT (1) PT1432417E (el)
RS (1) RS50896B (el)
SI (1) SI1432417T1 (el)
UY (1) UY27452A1 (el)
WO (1) WO2003028721A2 (el)
ZA (1) ZA200401887B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
JP2007527412A (ja) * 2003-10-24 2007-09-27 エグゼリクシス， インコーポレイテッド Ｔａｏキナーゼモジュレーターおよび使用方法
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
FR2868421B1 (fr) * 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
EP1598348A1 (en) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Novel pyridazinone derivatives as inhibitors of CDK2
US8044100B2 (en) 2004-12-22 2011-10-25 Bellus Health Inc. Methods and compositions for treating amyloid-related diseases
UA92180C2 (en) * 2005-09-06 2010-10-11 Смиткляйн Бичам Корпорейшн Benzimidazole thiophene compounds as plk inhibitors
FR2891273B1 (fr) * 2005-09-27 2007-11-23 Aventis Pharma Sa NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
KR101742179B1 (ko) 2006-10-12 2017-05-31 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
UA113277C2 (xx) * 2007-10-12 2017-01-10 Комбінація кристалічної форми1 2-((r)-2-метилпіролідин-2-іл)-1н-бензімідазол-4-карбоксаміду та протиракового лікарського засобу
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
FR2941950B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
WO2011091152A1 (en) * 2010-01-22 2011-07-28 Pablo Gastaminza Inhibitors of hepatitis c virus infection
IL310959A (en) 2015-08-25 2024-04-01 Alnylam Pharmaceuticals Inc Methods and preparations for treating a disorder related to the PCSK9 gene

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2441201C2 (de) * 1974-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Anthelminthisch wirksame 2-Carbalkoxyamino-5(6)-phenyl-sulfonyloxy-benzimidazole und Verfahren zu ihrer Herstellung
DE2541752A1 (de) * 1975-09-19 1977-03-24 Hoechst Ag Anthelminthisch wirksame 2-carbalkoxyamino-5(6)-phenyl-sulfonyloxy- benzimidazole und verfahren zu ihrer herstellung
DE3247615A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
PE20030427A1 (es) 2003-06-20
ZA200401887B (en) 2005-05-31
EA006802B1 (ru) 2006-04-28
CO5570675A2 (es) 2005-10-31
GT200200190A (es) 2003-11-11
MXPA04002042A (es) 2004-06-07
DE60225159D1 (de) 2008-04-03
NO20041214L (no) 2004-06-24
YU21404A (sh) 2006-08-17
MY135339A (en) 2008-03-31
UY27452A1 (es) 2003-02-28
PA8555501A1 (es) 2003-06-30
NO327008B1 (no) 2009-04-06
SI1432417T1 (sl) 2008-08-31
CN100346786C (zh) 2007-11-07
HRPK20040293B3 (en) 2007-06-30
CA2461622A1 (en) 2003-04-10
CA2461622C (en) 2008-12-02
ES2301682T3 (es) 2008-07-01
AU2002337151B2 (en) 2007-04-26
MEP16808A (en) 2010-06-10
EP1432417B1 (en) 2008-02-20
PL369527A1 (en) 2005-05-02
JP2005504112A (ja) 2005-02-10
HK1068551A1 (en) 2005-04-29
KR20040048904A (ko) 2004-06-10
HUP0401756A3 (en) 2005-06-28
EA200400475A1 (ru) 2004-08-26
CN1558761A (zh) 2004-12-29
KR100891439B1 (ko) 2009-04-03
HRP20040293A2 (en) 2005-06-30
WO2003028721A2 (en) 2003-04-10
US20050014811A1 (en) 2005-01-20
EP1432417A2 (en) 2004-06-30
DE60225159T2 (de) 2009-02-19
AR037096A1 (es) 2004-10-20
JP4510450B2 (ja) 2010-07-21
PT1432417E (pt) 2008-05-23
NZ531246A (en) 2006-06-30
ATE386517T1 (de) 2008-03-15
BR0212856A (pt) 2004-09-14
WO2003028721A3 (en) 2003-12-11
IL161059A0 (en) 2004-08-31
EP1298125A1 (en) 2003-04-02
HUP0401756A2 (hu) 2005-01-28
CY1107953T1 (el) 2013-09-04
US7041668B2 (en) 2006-05-09
RS50896B (sr) 2010-08-31

Similar Documents

Publication Publication Date Title
DK1432417T3 (da) Substituerede imidazolforbindelser og deres anvendelse til behandling af cancer
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
DK1083889T3 (da) Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
DK1455785T3 (da) Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse
DK1312922T3 (da) Nitritstabiliserende sammensætninger af tetrazoliumreagens og fremgangsmåder til deres anvendelse
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
NO20040469L (no) Heterocykliske forbindelser samt fremstilling og anvendelse derav
NO20042147L (no) Heterocykliske forbindelser og fremgangsmater for anvendelse derav
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1212317T3 (da) Indolderivater og anvendelse deraf til behandling af osteoporose blandt andre anvendelser
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
DK1176964T3 (da) Brug af ET743 til behandling af cancer
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DE60223576D1 (de) Hautbehandlungszusammensetzung
DK1589973T4 (da) Formulering og fremgangsmåder til behandling af thrombocytæmi
DK1472221T3 (da) Substituerede indoler, fremgangsmåde til fremstilling deraf og deres anvendelse til bekæmpelse af smerter
DK1694364T3 (da) System til behandling og forebyggelse af brystcancer
IS7166A (is) Notkun annellataðra pýrrólsambanda í meðhöndlun áliðabrjósks- eða neðanbrjósksbeinahrörnun
DK1537140T3 (da) Nukleinsyre og tilsvarende protein betegnet 161P2F10B, der er anvendelige i behandling og detektering af cancer